TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Strategies for Transfusion of Platelets (SToP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with hypoproliferative thrombocytopenia who are expected to have a platelet count of ≤ 10,000/µL (10x10\^9/L) for ≥ 10 days (Note: the prophylactic platelet trigger may be higher than10,000/µL (10x10\^9/L) in some participating institutions; however, the patient will still be eligible for participation as long as they are expected to be thrombocytopenic for 10 days)~* Must be an inpatient.~* Weight between 40 and 100 kg.~Exclusion Criteria:~* Diagnosis of promyelocytic leukemia.~* A history or current diagnosis of immune thrombocytopenia (ITP), thrombotic thrombocytopenia (TTP), or hemolytic uremia syndrome (HUS).~* Evidence of ≥ WHO Grade 2 bleeding while being assessed for the study entry.~* Patients who will receive bedside Leukoreduced platelet transfusions.~* Patients who are pregnant.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SARS-CoV-2 positive Real Time - Polymerase Chain Reaction~* Moderate to severe Acute respiratory distress syndrome according to Murray classification.~* PaO2/FiO2 less than 200 mmHg.~* Within 36 hours of orotracheal intubation.~* Absence of response with previous standard therapy.~* Willing to participate in the study expressed by patient or responsible caregiver.~* Not being in other clinical trial.~Exclusion Criteria:~* Current pregnancy.~* Cardiac rhythm abnormalities with instability.~* Acute congestive heart failure/cardiogenic shock.~* Severe comorbidities affecting mortality as defined by research group.~* Cancer history in the past 5 years.~* HIV, syphilis, hepatitis B or C.~* Concomitant use of immunosuppressive therapy with contraindication to MSC.~* Fivefold elevation of liver enzymes (ALT, AST).~* Chronic kidney disease with glomerular filtration rate below 30ml/min or dialytic needs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cell (Type: EXPERIMENTAL): WJ MSC 50\*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
- Control group (Type: ACTIVE_COMPARATOR): Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of the Implantation of a New Electrode for the Treatment of Dystonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age superior to 18 years and inferior to 65 years~* Generalized or segmental isolated dystonia or tardive dystonia~* Diagnosis is based on history, clinical examination, check-up without abnormalities and normal brain MRI allowing exclusion of secondary and degenerative dystonias~* Unsufficient response to pharmacological treatment (improvement \< 30/% on clinical dystonia scales)~* No comorbidity interfering with general anesthesia, or representing contraindication for neurosurgical procedure or with the follow-up during the trial~* Consent of the patient~* Insurance affiliation~* Follow-up possible for 12 months~* Available insurance for the operated patient~Exclusion Criteria:~* No possibility for clinical follow-up~* Acquired dystonia except for tardive dystonia~* MRI or generalized anesthesia contraindicated~* Anticoagulant treatment or antiaggregant treatment~* Pregnancy~* Ongoing participation to another clinical trial~* Guardianship or Trusteeship~* Person deprived of liberty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Electrode deep brain stimulation (Type: EXPERIMENTAL): Monocontact electrode deep brain stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ADX10059 Migraine Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 to 65 years~* History of migraine~* Aged ≤ 50 years at onset of migraine history~Exclusion Criteria:~* Cluster headache or chronic migraine headaches~* Currently uses, or within 3 months of Screening, has used: sodium valproate or topiramate and any other drugs used specifically for migraine prophylaxis, for example beta-blockers, calcium channel blockers, tricyclic antidepressants, selective serotonin reuptake inhibitors~* Unable to distinguish migraine headache from tension and other types of headache~* Current history of psychiatric disorder requiring regular medication~* Known history of alcohol abuse~* Known clinically significant allergy or known hypersensitivity to drugs~* History of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ADX10059 25 mg (Type: EXPERIMENTAL): Weeks 1-2: once daily Weeks 3-12: twice daily
- ADX10059 50 mg (Type: EXPERIMENTAL): Weeks 1-2: once daily Weeks 3-12: twice daily
- ADX10059 100 mg (Type: EXPERIMENTAL): Weeks 1-2: once daily Weeks 3-12: twice daily
- ADX10059 Matching Placebo (Type: PLACEBO_COMPARATOR): Weeks 1-2: once daily Weeks 3-12: twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of AIDET on Physician-Patient Communication

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Physicians: All physicians of the Hospital Medicine Service will be invited to participate~Exclusion Criteria:~* Any invited physicians who refuse to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Hospitalists (Type: None): AIDET Training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman over 18 years of age, less than 75 years~* Macular Hole of all etiologies~* Patient with history of opened macular hole after previous pars plana vitrectomy~* Delay between previous surgery and inclusion (relapse or non-closing hole) \> 1 month~* Patient who received the study information and provided consent~* Patient who is a members or a beneficiary of a national health insurance plan~Exclusion Criteria:~* Ocular surgery other than the macular hole surgery in the prior 3 months~* Participation in other clinical studies in the prior 3 months~* Any current or prior ocular pathology that could interfere with the conduct of the study, including visually significant cataract or media opacity~* Patient with uncontrolled glaucoma on more than 1 intraocular lowering medication~* Patient with uveitis or other active ocular inflammation or infection~* Pregnant or breast-feeding woman. Women of childbearing age will be asked to undergo a pregnancy test before being enrolled into the study or to use an effective birth control method~* Person deprived of liberty by judicial or administrative measures~* Any other reason which in the opinion of the investigator would preclude the adherence of the schedules visits, safe participation in the study or affect the results of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Visio-AMTRIX (Type: EXPERIMENTAL): Disk of amniotic membrane apposed or buried on recurrent macular hole by the Investigator after vitrectomy and fluid-gas exchange.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Signed informed consent must be obtained prior to participation in the study.~* Clinically diagnosed Stage 1 or 2 Huntington's disease with a diagnostic confidence level (DCL) = 4 and a United Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) \>8 at screening.~* Genetically confirmed Huntington's disease, with presence of ≥40 cytosine-adenineguanine (CAG) repeats in the huntingtin gene.~* Male and female participants between 25 to 75 years of age, inclusive, on the day of Informed Consent signature.~Exclusion Criteria~* Prior participation in clinical trial investigating a huntingtin-lowering therapy (unless participant received only placebo).~* Participants taking medications prohibited by the protocol.~* Any medical history, lumbar surgery or condition that would interfere with the ability to complete the protocol specified assessments.~* Participant has other severe, acute or chronic medical conditions including unstable psychiatric conditions, or laboratory abnormalities that in the opinion of the Investigator may increase the risk associated with study participation, or that may interfere with the interpretation of the study results.~* Any surgical or medical condition which might put the participant at risk in case of participation in the study. The Investigator should make this determination in consideration of the participant's medical history and/or clinical or laboratory evidence at the Screening visit.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm A (Type: EXPERIMENTAL): Branaplam 56 mg oral solution once weekly
- Treatment Arm B (Type: EXPERIMENTAL): Branaplam 112 mg oral solution once weekly
- Treatment Arm C or X or Y (Type: EXPERIMENTAL): (C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo oral solution once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* with neuropathic pain~* in the case of central lesions, the lesion must be unique and small~* treatment not stable opioid for one week~* consent signed~Exclusion Criteria:~* severe psychiatric history~* presence of an evolutive lesion, expansive, cancerous or tumorous underlying~* patient needing of opioid therapy~* contraindication at MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with pain allodynic peripheral (Type: OTHER): None
- patients with pain allodynic central (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Sweat Glucose of Patients With Diabetes - The ENGAGE Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with an existing diagnosis of diabetes mellitus, of any type, defined as having a fasting plasma glucose (FPG) \> 126 mg/dL, or hemoglobin A1c (HbA1c) \> 6.5%.~* Ability to provide informed consent for participation.~Exclusion Criteria:~* Individuals who do not have diabetes.~* Those who have an allergy to pilocarpine.~* Frequent episodes of low blood sugar (hypoglycemia), have no warning symptoms of hypoglycemia (hypoglycemia unawareness), or are at high risk of having hypoglycemia.~* If taking any of the following medications: any beta-blockers (including atenolol, carvedilol, metoprolol, and propanolol), chlorthalidone, hydrochlorothiazide, oxybutynin, and tiotropium.~* Individuals who have the following conditions, for which it is not safe to take pilocarpine, including:~Known or suspected gallstones or gallbladder disease~Kidney stones~Conditions that affect your thinking and/or memory, including Parkinson's disease and Alzheimer's disease~Asthma~Chronic obstructive pulmonary disease (COPD)~Glaucoma~Irritable Bowel Syndrome~Pregnancy - a pregnancy test will be obtained for each woman of child-bearing age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Diabetes (Type: EXPERIMENTAL): All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Kaletra and Viread in Antiretroviral Naïve Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients \>18 years of age with documented HIV-1 infection~2. Naïve to antiretroviral therapy~3. Able and willing to provide written informed consent~4. No CD4 restriction~5. HIV-1 RNA levels \>5000 c/mL~6. Female patients must meet these additional criteria~   1. Non-childbearing potential~  2. Negative serum pregnancy test at screen~  3. Willingness to abstain from sexual intercourse or use double barrier contraception~Exclusion Criteria:~1. Presence of any of the following:~   1. Aminotransferases \>3xULN~  2. Hemoglobin concentration \<8.0g/dl~  3. Absolute neutrophil count \<800 cells/cubic mm~  4. Platelet count \<50,000 cells/cubic mm~  5. Acute illness, or an acute illness ≤7 days~  6. Presence of Opportunistic Infection, or an OI within 30 days of screening~  7. Acute or chronic active Hepatitis B~  8. Hepatitis C~  9. Creatinine Clearance \<50 mL/min~2. Pregnant or breast-feeding women~3. Presence of any illness, physical or behavioral conditions (i.e., substance abuse, excluding cannabis) that will impair the patient's ability participate~4. Patient who, in the opinion of the investigator, will be unlikely to complete the study protocol and adhere to the study drug regimens~5. Concurrent use of medications that may potentially interact with study medications including: astemizole, terfenadine, rifampin, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, St. John's wort, lovastatin, simvastatin, pimozide, midazolam, triazolam, adefovir, cidofovir, acyclovir, ganciclovir, and valganciclovir.~6. Patient suffers from a serious medical condition that may in the opinion of the investigator compromise his or her safety.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Once daily (Type: EXPERIMENTAL): Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with histologically confirmed incident invasive breast cancer (T1-4) with no evidence of regional lymph node metastasis (N0) or distant metastasis (M0) and after complete primary tumor resection and axillary lymph node dissection less than 90 days before start of study drug treatment.~* Hormone receptor status is negative~* Patient is premenopausal (spontaneous and regular menses with premenopausal estradiol levels (\>10ng/dL)~* Patient receives adjuvant standard chemotherapy with approved cytotoxic chemotherapeutic drugs (e.g. AC 4-6 cycles) (prior neoadjuvant CT is allowed)~* Bone density at study entry \> -2.5 T-Score~Exclusion Criteria:~* Prior treatment with bisphosphonates and estrogens or treatments for osteoporosis in addition to calcium and vitamin D~* Severe physical or psychological concomitant diseases and other known concurrent, severe medical disorder jeopardizing the life of the patient in the immediate future (e.g., myocardial infarction in previous six months, angina pectoris despite treatment, uncontrolled severe arterial hypertension, progressive cardiac or respiratory failure)~* Known hypersensitivity to bisphosphonates~* Abnormal renal function~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures and recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid (Type: EXPERIMENTAL): Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.~* 18 years or older.~* At least one prior chemotherapy before entering in this trial.~* Not pregnant or breastfeeding.~Exclusion Criteria:~* Prior treatment with cabozantinib.~* Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).~* History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabozantinib + Pemetrexed (Type: EXPERIMENTAL): Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval